DexCom, Inc. (NASDAQ:DXCM) Shares Purchased by Steel Grove Capital Advisors LLC

Steel Grove Capital Advisors LLC boosted its holdings in DexCom, Inc. (NASDAQ:DXCM) by 11.8% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 2,850 shares of the medical device company’s stock after buying an additional 300 shares during the period. Steel Grove Capital Advisors LLC’s holdings in DexCom were worth $323,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of DXCM. Team Hewins LLC lifted its position in DexCom by 3.4% during the 1st quarter. Team Hewins LLC now owns 2,555 shares of the medical device company’s stock worth $354,000 after acquiring an additional 83 shares in the last quarter. Bleakley Financial Group LLC lifted its position in shares of DexCom by 1.3% during the first quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock worth $951,000 after purchasing an additional 87 shares in the last quarter. Capital Insight Partners LLC boosted its stake in shares of DexCom by 2.5% in the second quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock valued at $418,000 after purchasing an additional 90 shares during the period. Gulf International Bank UK Ltd grew its holdings in DexCom by 0.3% during the 1st quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company’s stock valued at $4,448,000 after purchasing an additional 93 shares in the last quarter. Finally, Harbor Investment Advisory LLC increased its stake in DexCom by 13.1% during the 1st quarter. Harbor Investment Advisory LLC now owns 864 shares of the medical device company’s stock worth $120,000 after buying an additional 100 shares during the period. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $69.70 on Tuesday. The company has a market cap of $27.72 billion, a PE ratio of 44.97, a P/E/G ratio of 2.12 and a beta of 1.18. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The firm has a 50-day simple moving average of $77.32 and a 200 day simple moving average of $108.93. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.39 by $0.04. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $1.04 billion. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The business’s revenue was up 15.3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.34 earnings per share. On average, sell-side analysts anticipate that DexCom, Inc. will post 1.69 EPS for the current year.

Analysts Set New Price Targets

DXCM has been the subject of a number of analyst reports. JPMorgan Chase & Co. cut shares of DexCom from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $145.00 to $75.00 in a research report on Friday, July 26th. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research note on Monday, June 10th. Barclays cut their target price on DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a research report on Monday, July 29th. Robert W. Baird raised their price target on shares of DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a research report on Monday, August 5th. Finally, Royal Bank of Canada cut their price target on shares of DexCom from $165.00 to $145.00 and set an “outperform” rating on the stock in a report on Friday, July 26th. Seven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $112.25.

Insider Buying and Selling

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Michael Jon Brown sold 659 shares of the company’s stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $114.29, for a total transaction of $75,317.11. Following the completion of the transaction, the executive vice president now owns 66,901 shares of the company’s stock, valued at approximately $7,646,115.29. The disclosure for this sale can be found here. Insiders sold a total of 2,483 shares of company stock worth $201,708 in the last three months. 0.30% of the stock is owned by insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.